You are here

  • Home
  • Archive
  • Volume 81, Issue 11
  • Response to: ‘Correspondence on ‘Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study’’ by Hung et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study’’ by Hung et al
  1. Hilde Berner Hammer1,2,
  2. Lars Fridtjof Karoliussen1,
  3. Lene Terslev3,
  4. Espen A Haavardsholm1,2,
  5. Tore K Kvien1,2,
  6. Till Uhlig1,2
  1. 1 Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  2. 2 University of Oslo, Faculty of Medicine, Oslo, Oslo, Norway
  3. 3 Centre for Rheumatology and Spinal Diseases, Glostrup, Rigshospitalet, Copenhagen, Denmark
  1. Correspondence to Dr Hilde Berner Hammer, Rheumatology, Diakonhjemmet Sykehus, 0370 Oslo, Norway; hbham{at}online.no

https://doi.org/10.1136/annrheumdis-2020-218908

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We appreciate the interest by Hung et al 1in our article describing the rapid reduction of ultrasound-detected crystal depositions in gout during 12 months of treat-to-target follow-up on urate-lowering treatment (ULT).

    Hung et al comment on the lack of control group in our study, and they suggest a double-blind, controlled study to explore the effectiveness of ULT, and they comment on the lack of information regarding blindness of operators and participants.1 We certainly agree on a randomised controlled trial (RCT) being necessary to confirm our findings, which are based on an observational study without a control group, where neither sonographers nor patients were blind to the treatment. However, since in addition to our study, several smaller studies have shown the reduction of urate depositions during ULT,2–6 and given the strong recommendations to reduce serum urate levels in gout to a …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Collaborators Not applicable.

    • Contributors HBH has written the draft and finalised the present comments to Hung et al. LK, LT, EAH, TKK and TU have all revised the manuscript critically for important intellectual content and given a final approval of the version to be published.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests Dr Hammer reports personal fees from AbbVie, Lilly and Novartis, outside the submitted work. Dr Karoliussen has nothing to disclose. Dr Terslev reports personal fees from Novartis, Roche, BMS and Pfizer outside the submitted work. Dr Haavardsholm reports personal fees from Pfizer, UCB, Eli Lilly, Celgene, Janssen-Cilag, AbbVie and Gilead outside the submitted work. Dr Kvien reports grants and personal fees from AbbVie, MSD, UCB, Hospira/Pfizer, Eli Lilly, grants from BMS, personal fees from Roche, Hikma, Orion, Sanofi, Celltrion, Sandoz, Biogen, Amgen, Egis, Ewopharma and Mylan, outside the submitted work. Dr Uhlig reports personal fees from Grünenthal and Novartis, outside the submitted work.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles